Functional role of Ile264 in CYP2C8: Mutations affect haem incorporation and catalytic activity

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 3, 2008, Pages 165-174

  Singh, Rajinder ^a   Ting, Jonathan G ^a   Pan, Yan ^a   Teh, Lay Kek ^b   Ismail, Rusli ^c   Ong, Chin Eng ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

CYP2C8*4; Genetic polymorphism; Paclitaxel; Pharmacogenomics; Site directed mutagenesis

Indexed keywords

CYTOCHROME P450 2C8; HEME; ISOLEUCINE; METHIONINE; OXYGENASE; PACLITAXEL; PROTEINASE K; TOLBUTAMIDE; CYP2C8 PROTEIN, HUMAN; PRIMER DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL CELL; BACTERIUM MUTANT; CATALYSIS; CONFORMATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; GENE MUTATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; SITE DIRECTED MUTAGENESIS; WILD TYPE; ANIMAL; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME STABILITY; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; RAT;

AMINO ACID SUBSTITUTION; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CATALYTIC DOMAIN; CLONING, MOLECULAR; DNA PRIMERS; ENDOPEPTIDASE K; ENZYME STABILITY; ESCHERICHIA COLI; HEME; HUMANS; ISOLEUCINE; MUTAGENESIS, SITE-DIRECTED; NADPH-FERRIHEMOPROTEIN REDUCTASE; PACLITAXEL; POLYMORPHISM, GENETIC; PROTEIN FOLDING; RATS; SUBSTRATE SPECIFICITY; TOLBUTAMIDE;

EID: 48849098300     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.165     Document Type: Article

References (37)

1. Goldstein, J. A. and de Morais, S. M.: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4: 285-299 (1994).
2. Goldstein, J. A.: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 52: 349-355 (2001).
3. Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I. and Goldstein, J. A.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11: 597-607 (2001).
4. Muthiah, Y. D., Lee, W. L., The, L. K., Ong C. E. and Ismail, R.: Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J. Clin. Pharm. Ther., 30: 487-490 (2005).
5. Soyama, A., Saito, Y., Komamura, K., Ueno, K., Kamakura, S., Ozawa, S. and Sawada, J.: Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab. Pharmacokinet., 17: 374-377 (2002).
6. Hichiya, H., Tanaka-Kagawa, T., Soyama, A., Jinno, H., Koyano, S., Katori, N., Matsushima, E., Uchiyama, S., Tokunaga, H., Kimura, H., Minami, N., Katoh, M., Sugai, K., Goto, Y., Tamura, T., Yamamoto, N., Ohe, Y., Kunitoh, H., Nokihara, H., Yoshida, T., Minami, H., Saijo, N., Ando, M., Ozawa, S., Saito, Y. and Sawada, J.: Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos., 33: 630-636 (2005).
7. Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., Williams, F. M., Armstrong, M., Crespi, C. L. and Daly, A. K.: CYP2C8 polymorphisms in Caucasian and their relationship with paclitaxel 6a-hydroxylase activity in human liver microsomes. Biochem. Pharmacol., 64: 1579-1589 (2002).
8. Nakajima, M., Fujiki, Y., Noda, K., Ohtsuka, H., Ohkuni, H., Kyo, S., Inoue, M., Kuroiwa, Y. and Yokoi, T.: Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos., 31: 687-690 (2003).
9. Boye, S. L., Kerdpin, O., Elliot, D. J., Miners, J. O., Kelly, L., McKinnon, R. A., Bhasker, C. R., Yoovathaworn, K. and Birkett, D. J.: Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica, 34: 49-60 (2004).
10. Shen, A. L., Porter, T. D., Wilson, T. E. and Kasper, C. B.: Structural analysis of the FMN binding domain of NADPHcytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem., 264: 7584-7589 (1989).
11. Gillam, E. M., Baba, T., Kim, B. R., Ohmori, S. and Guengerich, F. P.: Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys., 305: 123-131 (1993).
12. Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E. and Birkett, D. J.: Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol., 37: 1137-1144 (1988).
13. Crespi, C. L., Chang, T. K. and Waxman, D. J.: High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation. Meth. Mol. Biol., 320: 103-107 (2006).
14. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254 (1976).
15. Omura, T. and Sato, R.: The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239: 2370-2378 (1964).
16. Yasukochi, Y. and Masters, B. S.: Some properties of a detergent-solubilized NADPH cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem., 251: 5337-5344 (1976).
17. Relling, M. V., Aoyama, T., Gonzalez, F. J. and Meyer, U. A.: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther., 252: 442-447 (1990).
18. Veronese, M. E., Doecke, C. J., Mackenzie, P. I., McManus, M. E., Miners, J. O., Rees, D. L., Gasser, R., Meyer, U. A. and Birkett, D. J.: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J., 289: 533-538 (1993).
19. Csillag, K., Vereczkey, L. and Gachalyi, B.: Simple high-performance liquid chromatographic method for the determination of tolbutamide and its metabolites in human plasma and urine using photodiode-array detection. J. Chromatography, 490: 355-363 (1989).
20. Hansen, L. L. and Brosen, K.: Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection. Ther. Drug Monitor., 21: 664-671 (1999).
21. Cresteil, T., Monsarrat, B., Dubois, J., Sonnier, M., Alvinerie, P. and Gueritte, F.: Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab. Dispos., 30: 438-445 (2002).
22. Melet, A., Marques-Soares, C., Schoch, G. A., Macherey, A. C., Jaouen, M., Dansette, P. M., Sari, M. A., Johnson, E. F. and Mansuy, D.: Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry, 43: 15379-15392 (2004).
23. Taniguchi, R., Kumai, T., Matsumoto, N., Watanabe, M., Kamio, K., Suzuki, S. and Kobayashi, S.: Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J. Pharmacol. Sci., 97: 83-90 (2005).
24. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. and Collins, J. M.: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035 (1994).
25. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. and Harris, J. W.: Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54: 5543-5546 (1994).
26. Huizing, M. T., Sparreboom, A., Rosing, H., van Tellingen, O., Pinedo, H. M. and Beijnen, J. H.: Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J. Chromatography B, 674: 261-268 (1995).
27. Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D. and Johnson, E. F.: Structure of Human Microsomal Cytochrome P450 2C8: Evidence for a peripheral fatty acid binding site. J. Biol. Chem., 279: 9497-9503 (2004).
28. Pritchard, M. P., Ossetian, R., Li, D. N., Henderson, C. J., Burchell, B., Wolf C. R. and Friedberg, T.: A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch. Biochem. Biophys., 345: 342-354 (1997).
29. Pritchard, M. P., Glancey, M. J., Blake, J. A., Gillam, D. E., Burchell, B., Wolf, C. R. and Friedberg, T.: Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8: 33-42 (1998).
30. Hsu, L. C., Hsu, N. C., Guzova, J. A., Guzov, V.M., Chang, S. F. and Chung, B. C.: The common I172N mutation causes conformational change of cytochrome P450c21 revealed by systematic mutation, kinetic, and structural studies. J. Biol. Chem., 271: 3306-3310 (1996).
31. Ebeling, W., Hennrich, N., Klockow, M., Metz, H., Orth, H. D. and Lang, H.: Proteinase K from Tritiachium album Limber. Eur. J. Biochem., 47: 91-97 (1974).
32. Kraus, E. and Femfert, U.: Proteinase K from the mold Tritirachium album Limber. Specificity and mode of action. Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 357: 937-947 (1976).
33. Kim, K. A., Chung, J., Jung, D. H. and Park, J. Y.: Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol., 60: 575-581 (2004).
34. Walsky, R. L., Obach, R. S., Gaman, E. A., Gleeson, J. P. and Proctor, W. R.: Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos., 33: 413-418 (2005).
35. Krone, N., Riepe, F. G., Grotzinger, J., Partsch, C. J., Bramswig, J. and Sippell, W. G.: The residue E351 is essential for the activity of human 21-hydroxylase: evidence from a naturally occurring novel point mutation compared with artificial mutants generated by single amino acid substitutions. J. Mol. Med., 83: 561-568 (2005).
36. He, X. Y., Shen, J., Ding, X., Lu, A. Y. and Hong, J. Y.: Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab. Dispos.,32: 1516-1521 (2004).
37. Lewis, D. F. V.: Homology modelling of human CYP2 family enzymes based on the CYP2C5 cystal structure. Xenobiotica, 32: 305-323 (2002).